Yann Touchefeu - Concepedia

Author

Yann Touchefeu

Also Known As

Claire Stampfli, David Malka, E Thibaudeau, E. Thibaudeau, Emilie Thibaudeau, Raphaël Tetreau, Rosine Guimbaud, Y Touchefeu, Y. TOUCHEFEU, Y. Touchefeu

177

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Inserm Nantes Université Centre Hospitalier Universitaire de Nantes Assistance Publique – Hôpitaux de Paris Université de Poitiers

About

Yann Touchefeu is an author at Inserm specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	703
2	Health Sciences	4	4	107
3	Engineering	1	1	58
4	Public Health	1	1	75
5	Biomedical Engineering	1	1	58

Yann Touchefeu

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma Julien Edeline, Yann Touchefeu, Boris Guiu, JAMA Oncology	2019	277
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial Thierry André, Elena Élez, Heinz‐Josef Lenz, The Lancet MedicineColorectal CancerPathologyImmune Checkpoint InhibitorIpilimumab Versus Nivolumab	2025	115
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study David Tougeron, Benjamin Sueur, Aziz Zaanan, International Journal of Cancer Cancer EpidemiologyGastrointestinal OncologyMedicineDmmr/msi Mcrc PatientsColorectal Cancer	2020	75
Colorectal Cancer Cells Adhere to and Migrate Along the Neurons of the Enteric Nervous System Émilie Duchalais, Christophe Guilluy, Steven Nédellec, Cellular and Molecular Gastroenterology and Hepatology	2017	63
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial Philippe Merle, Jean‐Frédéric Blanc, Jean–Marc Phelip, The Lancet. Gastroenterology & hepatology NanoparticlesNanomedicineSorafenib Treatment FailureOncologyHepatology	2019	58
Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study Maëva Salimon, Caroline Prieux‐Klotz, David Tougeron, British Journal of Cancer	2017	54
Endoscopic ultrasound‐guided fine‐needle aspiration for the diagnosis of solid pancreatic masses: the impact on patient‐management strategy Yann Touchefeu, Marc Le Rhun, E Coron, Alimentary Pharmacology & Therapeutics	2009	50
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations Cindy Neuzillet, Andrea Casadei‐Gardini, Bertrand Brieau, European Journal of Cancer MedicineBiliary CancerPrognosisPathologyBiliary Tract Cancer	2019	45
Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling Joan Kyula, Aadil Khan, David Mansfield, Oncogene Cancer ImmunosurveillanceMedicinePathogenesisImmunologyMelanoma	2013	43
Oncolytic Vaccinia virus and radiotherapy in head and neck cancer David Mansfield, T. Pencavel, Joan Kyula, Oral Oncology VaccinationOncolytic Vaccinia VirusMedicineImmunologyNasopharyngeal Cancer	2012	35

Page 1